Autolus Therapeutics PLC (AUTL)
Stock Price:
$14.90 USD
-1.10 (-6.88%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
778.49M |
| Revenue (ttm) |
1.08M |
| Net Income (ttm) |
-126.54M |
| Shares Out |
52.25M |
| EPS (ttm) |
-1.40 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$14.90 |
| Previous Close |
$16.00 |
| Change ($) |
-1.10 |
| Change (%) |
-6.88% |
| Day's Open |
15.49 |
| Day's Range |
14.57 - 15.99 |
| Day's Volume |
192,637 |
| 52-Week Range |
3.00 - 19.34 |
More Stats
| Market Cap |
778.49M |
| Enterprise Value |
561.05M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
52.25M |
| Float |
33.90M |
| EPS (basic) |
-2.79 |
| EPS (diluted) |
-1.40 |
| FCF / Share |
-2.26 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
850,083 |
| Short Ratio |
4.27 |
| Short % of Float |
n/a |
| Beta |
2.08 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
721.83 |
| PB Ratio |
2.85 |
| Revenue |
1.08M |
| Operating Income |
-154.47M |
| Net Income |
-126.54M |
| Free Cash Flow |
-112.65M |
| Net Cash |
217.44M |
| Net Cash / Share |
4.16 |
| Gross Margin |
-9,504.87% |
| Operating Margin |
-14,322.48% |
| Profit Margin |
-9,870.70% |
| FCF Margin |
-10,444.88% |
| ROA |
-22.28% |
| ROE |
-29.62% |
| ROIC |
-156.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
6 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$27.33*
(83.42% upside)
Low
13.0
Current: 14.90
High
50.0
Target: 27.33
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 2.91 | 1.41 | 1.69 | 1.21 |
| Revenue Growth | 106.68% | -16.89% | 39.69% | - |
| Gross Profit | 2.91 | 1.41 | 1.69 | 1.21 |
| Operating Income | -146 | -57.53 | -23.42 | -14.38 |
| Net Income | -124 | -44.75 | -19.73 | -12.55 |
| Shares Outstanding | 43.07 | 31.56 | 13.78 | 9.93 |
| Earnings Per Share | -2.88 | -1.42 | -1.43 | -1.26 |
| Operating Cash Flow | -101 | -31.54 | -16.36 | -9.85 |
| Capital Expenditures | -18.34 | -9.12 | -2.88 | -1.86 |
| Free Cash Flow | -120 | -40.66 | -19.24 | -11.70 |
| Cash & Equivalents | 211 | 189 | 102 | 28.06 |
| Total Debt | 26.22 | - | - | 0.19 |
| Net Cash / Debt | 185 | 189 | 102 | 27.87 |
| Assets | 304 | 218 | 117 | 34.18 |
| Liabilities | 48.69 | 12.52 | 3.62 | 3.49 |
| Book Value | 255 | 205 | 114 | 30.69 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Autolus Therapeutics PLC |
| Country |
United Kingdom |
| Employees |
290 |
| CEO |
Christian Martin Itin |
Stock Information
| Ticker Symbol |
AUTL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AUTL |
| IPO Date |
June 22, 2018 |
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.